Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Price
RXRXStock
$3.46−45.52%52W
Market Cap$1.86B
P/E—
PEG Ratio—
Div yield—
Beta1.19
RXRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-12.02%
Price vs S&P 500 (4W)-11.40%
VGM Score44.70
RXRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.23 | -$0.25 | -6.84%(-$0.02) | |
| Q1 2026 | -$0.26 | -$0.22 | +14.44%(+$0.04) | |
| Q4 2025 | -$0.32 | -$0.21 | +33.34%(+$0.11) | |
| Q3 2025 | -$0.38 | -$0.36 | +5.68%(+$0.02) | |
| Q2 2025 | -$0.35 | -$0.41 | -16.04%(-$0.06) |
RXRX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.71
3.71
3.77
3.77
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock | D | C | C | 33.9x | -15.1% | 3.5% | — | $3.46 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Recursion Pharmaceuticals, Inc. Class A Common Stock
Recursion Pharmaceuticals is a clinical-stage biotech company that integrates computational and experimental technologies—including chemistry, automation, and data science—to accelerate drug discovery and industrialize development. The platform aims to decode biological processes and de-risk the path from research to therapeutic approval. U.S. operations represent the company's primary revenue source, with additional presence in the United Kingdom and other markets.